128 related articles for article (PubMed ID: 32951893)
41. Chemoradiation in cervical cancer with cisplatin and high-dose rate brachytherapy combined with external beam radiotherapy. Results of a phase-II study.
Strauss HG; Kuhnt T; Laban C; Puschmann D; Pigorsch S; Dunst J; Koelbl H; Haensgen G
Strahlenther Onkol; 2002 Jul; 178(7):378-85. PubMed ID: 12163992
[TBL] [Abstract][Full Text] [Related]
42. Mutational analysis of KRAS and its clinical implications in cervical cancer patients.
Jiang W; Xiang L; Pei X; He T; Shen X; Wu X; Yang H
J Gynecol Oncol; 2018 Jan; 29(1):e4. PubMed ID: 29185262
[TBL] [Abstract][Full Text] [Related]
43. Treatment of advanced cervical cancer: a population-based study.
Cairns M; Harry V; Sarkar TK; Parkin DE
Eur J Cancer Care (Engl); 2008 Nov; 17(6):565-8. PubMed ID: 18771538
[TBL] [Abstract][Full Text] [Related]
44. Are increased tumor aneuploidy and heightened cell proliferation along with heterogeneity associated with patient outcome for carcinomas of the uterine cervix? A combined analysis of subjects treated in RTOG 9001 and a single-institution trial.
Wolfson AH; Winter K; Crook W; Krishan A; Grigsby PW; Markoe AM; Morris M; Gaffney DK; Eifel PJ; Lucci JA
Int J Radiat Oncol Biol Phys; 2008 Jan; 70(1):111-7. PubMed ID: 17919835
[TBL] [Abstract][Full Text] [Related]
45. Prognostic value of pretreatment factors in patients with locally advanced carcinoma of the uterine cervix treated by radiotherapy alone.
Pedersen D; Søgaard H; Overgaard J; Bentzen SM
Acta Oncol; 1995; 34(6):787-95. PubMed ID: 7576747
[TBL] [Abstract][Full Text] [Related]
46. Comparison of Lower Extremity Edema in Locally Advanced Cervical Cancer: Pretreatment Laparoscopic Surgical Staging with Tailored Radiotherapy Versus Primary Radiotherapy.
Kim SI; Lim MC; Lee JS; Kim YJ; Seo SS; Kang S; Yoo CW; Nam BH; Kim JY; Chung SH; Park SY
Ann Surg Oncol; 2016 Jan; 23(1):203-10. PubMed ID: 26059654
[TBL] [Abstract][Full Text] [Related]
47. HPV-negative carcinoma of the uterine cervix: a distinct type of cervical cancer with poor prognosis.
Rodríguez-Carunchio L; Soveral I; Steenbergen RD; Torné A; Martinez S; Fusté P; Pahisa J; Marimon L; Ordi J; del Pino M
BJOG; 2015 Jan; 122(1):119-27. PubMed ID: 25229645
[TBL] [Abstract][Full Text] [Related]
48. Treatment results of high-dose-rate remote afterloading brachytherapy for cervical cancer and retrospective comparison of two regimens.
Wong FC; Tung SY; Leung TW; Sze WK; Wong VY; Lui CM; Yuen KK; O SK
Int J Radiat Oncol Biol Phys; 2003 Apr; 55(5):1254-64. PubMed ID: 12654435
[TBL] [Abstract][Full Text] [Related]
49. Measurement of tumor volume by PET to evaluate prognosis in patients with advanced cervical cancer treated by radiation therapy.
Miller TR; Grigsby PW
Int J Radiat Oncol Biol Phys; 2002 Jun; 53(2):353-9. PubMed ID: 12023139
[TBL] [Abstract][Full Text] [Related]
50. Next-Generation Sequencing of a Cohort of Pulmonary Large Cell Carcinomas Reclassified by World Health Organization 2015 Criteria.
Driver BR; Portier BP; Mody DR; Deavers M; Bernicker EH; Kim MP; Teh BS; Santacruz JF; Kopas L; Munden RF; Cagle PT
Arch Pathol Lab Med; 2016 Apr; 140(4):312-7. PubMed ID: 26430808
[TBL] [Abstract][Full Text] [Related]
51. A feasibility study of topotecan with standard-dose cisplatin and concurrent primary radiation therapy in locally advanced cervical cancer.
Gatcliffe TA; Tewari KS; Shah A; Brewster WR; Burger RA; Kuo JV; Monk BJ
Gynecol Oncol; 2009 Jan; 112(1):85-9. PubMed ID: 18977518
[TBL] [Abstract][Full Text] [Related]
52. No prognostic impact of flow-cytometric measured DNA ploidy and S-phase fraction in cancer of the uterine cervix: a prospective study of 465 patients.
Kristensen GB; Kaern J; Abeler VM; Hagmar B; Tropé CG; Pettersen EO
Gynecol Oncol; 1995 Apr; 57(1):79-85. PubMed ID: 7705705
[TBL] [Abstract][Full Text] [Related]
53. Combined external and intracavitary irradiation in treatment of advanced cervical carcinomas: predictive factors for treatment outcome and early and late radiation reactions.
Bohr Mordhorst L; Karlsson L; Bärmark B; Sorbe B
Int J Gynecol Cancer; 2014 Sep; 24(7):1268-75. PubMed ID: 25078336
[TBL] [Abstract][Full Text] [Related]
54. Adenosquamous carcinoma versus adenocarcinoma in early-stage cervical cancer patients undergoing radical hysterectomy: an outcomes analysis.
dos Reis R; Frumovitz M; Milam MR; Capp E; Sun CC; Coleman RL; Ramirez PT
Gynecol Oncol; 2007 Dec; 107(3):458-63. PubMed ID: 17854872
[TBL] [Abstract][Full Text] [Related]
55. Assessment of cytology based molecular analysis to guide targeted therapy in advanced non-small-cell lung cancer.
Li W; Zhang Z; Guo L; Qiu T; Ling Y; Cao J; Guo H; Zhao H; Li L; Ying J
Oncotarget; 2016 Feb; 7(7):8332-40. PubMed ID: 26789109
[TBL] [Abstract][Full Text] [Related]
56. Carcinoma of the uterine cervix in Saudi Arabia: experience in the management of 164 patients with stage-I & -II disease.
El-Senoussi M; Bakri Y; Amer MH; DeVol EB
Int J Radiat Oncol Biol Phys; 1998 Aug; 42(1):91-100. PubMed ID: 9747825
[TBL] [Abstract][Full Text] [Related]
57. Comprehensive mapping of the human papillomavirus (HPV) DNA integration sites in cervical carcinomas by HPV capture technology.
Liu Y; Lu Z; Xu R; Ke Y
Oncotarget; 2016 Feb; 7(5):5852-64. PubMed ID: 26735580
[TBL] [Abstract][Full Text] [Related]
58. High-dose-rate intracavitary brachytherapy combined with external beam radiotherapy for stage IIIb adenocarcinoma of the uterine cervix in Japan: a multi-institutional study of Japanese Society of Therapeutic Radiology and Oncology 2006-2007 (study of JASTRO 2006-2007).
Niibe Y; Kenjo M; Onishi H; Ogawa Y; Kazumoto T; Ogino I; Tsujino K; Harima Y; Takahashi T; Anbai A; Tsuchida E; Toita T; Takemoto M; Yamashita H; Hayakawa K
Jpn J Clin Oncol; 2010 Aug; 40(8):795-9. PubMed ID: 20444747
[TBL] [Abstract][Full Text] [Related]
59. Distinctive clinicopathologic characteristics and prognosis for different histologic subtypes of early cervical cancer.
Cao L; Wen H; Feng Z; Han X; Wu X
Int J Gynecol Cancer; 2019 Oct; 29(8):1244-1251. PubMed ID: 31422351
[TBL] [Abstract][Full Text] [Related]
60. Abnormalities of epidermal growth factor receptor in lung squamous-cell carcinomas, adenosquamous carcinomas, and large-cell carcinomas: tyrosine kinase domain mutations are not rare in tumors with an adenocarcinoma component.
Ohtsuka K; Ohnishi H; Fujiwara M; Kishino T; Matsushima S; Furuyashiki G; Takei H; Koshiishi Y; Goya T; Watanabe T
Cancer; 2007 Feb; 109(4):741-50. PubMed ID: 17238183
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
